Ftse Mib
35.434,95
0,07%
DAX
18.686,42
-0,21%
S&P 500
5.297,10
-0,21%
NASDAQ
16.698,32
-0,26%
Bitcoin
66.237,50
1,53%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Evoke Pharma Inc (EVOK) Evoke Pharma Inc (EVOK) Notizie

EVOK

Evoke Pharma (EVOK)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EVOK
DataOraFonteTitoloSimboloCompagnia
16/05/202422:02GlobeNewswire Inc.Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) ConferenceNASDAQ:EVOKEvoke Pharma Inc
14/05/202422:58Edgar (US Regulatory)Form ARS/A - Annual Report to Security Holders: [Amend]NASDAQ:EVOKEvoke Pharma Inc
14/05/202422:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EVOKEvoke Pharma Inc
14/05/202422:15GlobeNewswire Inc.Evoke Pharma Reports First Quarter 2024 Financial ResultsNASDAQ:EVOKEvoke Pharma Inc
14/05/202422:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EVOKEvoke Pharma Inc
14/05/202422:05Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:EVOKEvoke Pharma Inc
17/04/202414:30GlobeNewswire Inc.Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 MedicationsNASDAQ:EVOKEvoke Pharma Inc
21/03/202421:15GlobeNewswire Inc.Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive OfficerNASDAQ:EVOKEvoke Pharma Inc
14/03/202421:05GlobeNewswire Inc.Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:EVOKEvoke Pharma Inc
07/03/202422:10GlobeNewswire Inc.Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024NASDAQ:EVOKEvoke Pharma Inc
20/02/202422:38Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:EVOKEvoke Pharma Inc
14/02/202413:30GlobeNewswire Inc.Evoke Pharma Announces Closing of $7.5 Million Public OfferingNASDAQ:EVOKEvoke Pharma Inc
09/02/202423:14Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:EVOKEvoke Pharma Inc
09/02/202413:30GlobeNewswire Inc.Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 MillionNASDAQ:EVOKEvoke Pharma Inc
09/02/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:EVOKEvoke Pharma Inc
08/02/202412:50Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:EVOKEvoke Pharma Inc
27/11/202314:30GlobeNewswire Inc.Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI PatentNASDAQ:EVOKEvoke Pharma Inc
14/11/202314:30GlobeNewswire Inc.United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTINASDAQ:EVOKEvoke Pharma Inc
09/11/202322:30Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:EVOKEvoke Pharma Inc
09/11/202314:30GlobeNewswire Inc.Evoke Pharma Reports Third Quarter 2023 Financial ResultsNASDAQ:EVOKEvoke Pharma Inc
31/10/202313:30GlobeNewswire Inc.Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023NASDAQ:EVOKEvoke Pharma Inc
18/10/202314:30GlobeNewswire Inc.Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 20NASDAQ:EVOKEvoke Pharma Inc
14/09/202314:30GlobeNewswire Inc.Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®NASDAQ:EVOKEvoke Pharma Inc
11/08/202315:01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:EVOKEvoke Pharma Inc
10/08/202314:30GlobeNewswire Inc.Evoke Pharma Reports Second Quarter 2023 Financial ResultsNASDAQ:EVOKEvoke Pharma Inc
07/08/202314:30GlobeNewswire Inc.Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) MeetingNASDAQ:EVOKEvoke Pharma Inc
25/07/202314:30GlobeNewswire Inc.Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual MeetingNASDAQ:EVOKEvoke Pharma Inc
14/06/202314:30GlobeNewswire Inc.Evoke Pharma to Host First Key Opinion Leader Webinar on Healthcare Resource Utilization Data Related to Gastroparesis and its TreatmentNASDAQ:EVOKEvoke Pharma Inc
26/05/202323:05Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:EVOKEvoke Pharma Inc
18/05/202321:43Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:EVOKEvoke Pharma Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EVOK

La tua Cronologia

COIN
PLTCCBTC
USOTC
QPRC
Quest Patent Research (QB)
CSE
GDIG
Gold Digger Resources
COIN
DVTBTC
DeVault
COIN
BLYBTC
Blocery Token
DOWI
DJUSCT
DJ US Telecommunications...
BIT
UI360C
Unicredit Bank
GATE
IHCUSDT
Inflation Hedging Coin
COIN
MINIUSD
MINISWAP
COIN
KNGGBP
COIN
ESHIPEUR
NYSE
PCG.U
PG&E
ASX
PV1
Provaris Energy
LSE
UCAP
Cape Us-usd
LSE
33XA
Assa 25
ASX
ANZLOL
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network